MX2022008949A - Formulacion de anticuerpos estable. - Google Patents
Formulacion de anticuerpos estable.Info
- Publication number
- MX2022008949A MX2022008949A MX2022008949A MX2022008949A MX2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- ebov
- present disclosure
- storage
- antibody formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241001115402 Ebolavirus Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000013019 agitation Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación proporciona formulaciones farmacéuticas estables que comprenden un anticuerpo humano que se une específicamente al virus del Ébola (EBOV). En ciertas modalidades, las formulaciones contienen, además de un anticuerpo anti-EBOV, un amortiguador, un aminoácido, un surfactante no iónico y un estabilizador. Las formulaciones farmacéuticas de la presente divulgación exhiben un grado sustancial de estabilidad de anticuerpos frente al estrés, por ejemplo, agitación durante el transporte y almacenamiento, por ejemplo, almacenamiento a temperaturas mayores que 40 °C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062965786P | 2020-01-24 | 2020-01-24 | |
PCT/US2021/014524 WO2021150829A1 (en) | 2020-01-24 | 2021-01-22 | Stable antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008949A true MX2022008949A (es) | 2022-08-15 |
Family
ID=74858743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008949A MX2022008949A (es) | 2020-01-24 | 2021-01-22 | Formulacion de anticuerpos estable. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210252146A1 (es) |
EP (1) | EP4093435A1 (es) |
JP (1) | JP2023511080A (es) |
KR (1) | KR20220131923A (es) |
CN (1) | CN115243718A (es) |
AU (1) | AU2021210942A1 (es) |
BR (1) | BR112022014240A2 (es) |
CA (1) | CA3162569A1 (es) |
CL (2) | CL2022001989A1 (es) |
CO (1) | CO2022010254A2 (es) |
IL (1) | IL294375A (es) |
MX (1) | MX2022008949A (es) |
WO (1) | WO2021150829A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200148750A1 (en) | 2016-07-21 | 2020-05-14 | Emory University | Ebola Virus Antibodies and Binding Agents Derived Therefrom |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
WO2001016183A1 (en) | 1999-08-30 | 2001-03-08 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
ES2728095T3 (es) | 2008-02-01 | 2019-10-22 | Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Health | Anticuerpos monoclonales para los virus del Ebola y Marburgo |
AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
CA2741523C (en) | 2008-10-24 | 2022-06-21 | Jonathan S. Towner | Human ebola virus species and compositions and methods thereof |
KR102031020B1 (ko) * | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
BR112019022698A2 (pt) * | 2017-05-02 | 2020-05-19 | Merck Sharp & Dohme | formulações estáveis de anticorpos anti-tigit isolados e em combinação com anticorpos do receptor de morte programada 1 (pd-1) e métodos de uso das mesmas |
CN112004553A (zh) * | 2018-04-25 | 2020-11-27 | 免疫医疗有限公司 | 人抗pd-l1抗体的配制品 |
-
2021
- 2021-01-22 CA CA3162569A patent/CA3162569A1/en active Pending
- 2021-01-22 MX MX2022008949A patent/MX2022008949A/es unknown
- 2021-01-22 US US17/155,432 patent/US20210252146A1/en active Pending
- 2021-01-22 JP JP2022543445A patent/JP2023511080A/ja active Pending
- 2021-01-22 WO PCT/US2021/014524 patent/WO2021150829A1/en unknown
- 2021-01-22 CN CN202180010566.0A patent/CN115243718A/zh active Pending
- 2021-01-22 BR BR112022014240A patent/BR112022014240A2/pt unknown
- 2021-01-22 EP EP21710081.7A patent/EP4093435A1/en active Pending
- 2021-01-22 KR KR1020227025939A patent/KR20220131923A/ko unknown
- 2021-01-22 AU AU2021210942A patent/AU2021210942A1/en active Pending
- 2021-01-22 IL IL294375A patent/IL294375A/en unknown
-
2022
- 2022-07-20 CO CONC2022/0010254A patent/CO2022010254A2/es unknown
- 2022-07-22 CL CL2022001989A patent/CL2022001989A1/es unknown
-
2023
- 2023-08-30 CL CL2023002560A patent/CL2023002560A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN115243718A (zh) | 2022-10-25 |
US20210252146A1 (en) | 2021-08-19 |
JP2023511080A (ja) | 2023-03-16 |
IL294375A (en) | 2022-08-01 |
AU2021210942A1 (en) | 2022-07-14 |
EP4093435A1 (en) | 2022-11-30 |
KR20220131923A (ko) | 2022-09-29 |
CL2023002560A1 (es) | 2024-03-01 |
BR112022014240A2 (pt) | 2022-12-13 |
WO2021150829A1 (en) | 2021-07-29 |
CO2022010254A2 (es) | 2022-08-09 |
CA3162569A1 (en) | 2021-07-29 |
CL2022001989A1 (es) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502123A1 (en) | Stable antibody formulation | |
CY1121420T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
ES2537963T3 (es) | Estabilización de composiciones acuosas de proteínas con tampones de desplazamiento | |
AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
MX2015001217A (es) | Formulacion liquida de insulina de accion prolongada y de peptido insulinotropico. | |
MY193913A (en) | Stable Protein Solution Formulation Containing High Concentration of an Anti-Vegf Antibody | |
MX369479B (es) | Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada. | |
TN2009000382A1 (en) | Stable antibody formulations | |
MY197773A (en) | Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody | |
MX2022014596A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
WO2012076670A3 (en) | Antibody formulation | |
WO2010100200A3 (en) | Lyophilised antibody formulation | |
MX2021011137A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33. | |
MX2022008949A (es) | Formulacion de anticuerpos estable. | |
BR112021019612A2 (pt) | Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa | |
CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
ZA202204982B (en) | Stable formulation of integrin antibody | |
JP6857613B2 (ja) | タンパク質の安定化 | |
MX2022016403A (es) | Formulaciones de anticuerpo de activina a y métodos para utilizarlas. | |
TN2012000342A1 (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |